Drug
Remigromig
Remigromig: highest development phase Phase 2/3, developed by EyeBiotech Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- EyeBiotech Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| Remigromig NCT06571045 | Phase 2/3 | Diabetic Macular Edema (DME) |
Latest
No recent events.
Follow Remigromig on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.